Abstract 563P
Background
Osimertinib, the standard first-line therapy for EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC), preliminarily demonstrated similar clinical effectiveness to the landmark FLAURA study in the prospective, non-interventional, real-world FLOURISH study at the first interim analysis. This report presents an updated effectiveness and safety results.
Methods
A total of 500 patients were recruited into the FLOURISH study from 22 sites in China between July 27, 2020, and April 27, 2022. This analysis included 460 patients who met the eligibility criteria and received at least one dose of osimertinib after enrolment and without protocol violation into the full analysis set (FAS) for effectiveness analysis, and 495 patients who received at least one dose of osimertinib after enrolment into the safety set (SS). The data cut-off date was June 30, 2023.
Results
Of the 460 patients in FAS, the median age was 64.1 years (range: 27-88), 62.4% were female, 64.8% had comorbidities, 35.0% with CNS metastases, and 98.7% in stage IIIB-IV. The objective response rate (ORR) was 61.8% (238/385), and disease control rate (DCR) was 96.1% (370/385) in evaluable patients. With a median follow-up of 18.0 months, the 1-year progression-free survival (PFS) and 1-year overall survival (OS) rate was 79.6% (95%CI: 75.0%-83.3%) and 90.0% (95%CI: 86.8%-92.5%), respectively. In patients with CNS metastases, ORR was 63.8% (90/141), DCR was 95.0% (134/141), 1-year PFS rate was 78.9%, and 1-year OS rate was 90.1%. Moreover, patients with exon 19 deletion (n=235) had higher 1-year PFS (84.2% vs. 75.0%) and 1-year OS (93.4% vs. 86.8%) rates than patients with exon 21 L858R (n=212). Among the 495 patients in SS, 195 patients (39.4%) experienced adverse events (AEs), with 18(3.6%) of grade ≥3. AEs leading to dose interruption or discontinuation were reported in 3 (0.6%) and 12(2.4%) patients, respectively.
Conclusions
The FLOURISH study showed consistence with FLAURA in terms of effectiveness of first-line osimertinib for Chinese patients with advanced EGFRm-NSCLC in real world setting. No new safety signals were observed. The follow-up is still ongoing and the final analysis is expected in future.
Clinical trial identification
NCT04391283.
Editorial acknowledgement
Legal entity responsible for the study
Guangdong Association of Clinical Trials.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract